Interleukin (IL)-12 and granulocyte-monocyte colony-stimulating factor (GM-CSF) have recently been used as immunotherapeutic agents in cancer gene therapy. IL-12 and GM-CSF have differential roles in the antitumor immune response, as IL-12 targets T, NK and natural killer T (NKT) cells and GM-CSF principally targets antigen-presenting cells (APCs). To strengthen the therapeutic efficacy of these two cytokines, we generated an oncolytic adenovirus (Ad), Ad-DB7/IL12/GMCSF, coexpressing IL-12 and GM-CSF. Using a murine B16-F10 syngeneic tumor model, we show that Ad-DB7/IL12/GMCSF promoted antitumor responses and increased survival compared with an oncolytic Ad expressing IL-12 or GM-CSF alone (Ad-DB7/IL12 or Ad-DB7/GMCSF, respectively). By measuring cytotoxic T lymphocyte activity and interferon-g production, we show that the enhanced therapeutic effect was mediated by the induction of immune cell cytotoxicity. In situ delivery of Ad-DB7/IL12/GMCSF resulted in massive infiltration of CD4 + T cells, CD8 + T cells, NK cells and CD86 + APCs into the tissue surrounding the necrotic area of the tumor. Moreover, GM-CSF effectively promoted antitumor immune memory, which was significantly augmented by IL-12. Lastly, IL12-expressing oncolytic Ads prevented tumor-induced thymic atrophy and was associated with reduced apoptosis and increased proliferation in the thymus. Taken together, these data demonstrate that an oncolytic Ad coexpressing IL-12 and GM-CSF is a potential therapeutic tool for the treatment of cancer.
INTRODUCTION
Cancer cells suppress the immune system via the induction of anergy or tolerance in the host immune system, ultimately enabling the cancer cells to uncontrollably proliferate in the host. 1 Many methods of cancer immunotherapy have focused on overcoming immune modulation by the cancer cells and inducing a tumor-specific immune response. 2 Immunogene therapy is one cancer immunotherapeutic strategy that involves the transfer of immune genes into cancer tissue to induce an antitumor immune response. Many immune stimulatory factors have been used in cancer gene therapy, including chemokines, costimulators and cytokines. [3] [4] [5] Cytokines are heterogeneous family of polypeptide mediators, which are an essential component of innate and adaptive immunity, and that are associated with the transmission of cellular signals for regulation of the immune system. Because of their regulatory capabilities, cytokines have been regarded as suitable candidate molecules for cancer immunotherapy.
Interleukin (IL)-12 is a 70-kDa heterodimeric cytokine that is an important regulator of the innate and adaptive immune response. IL-12 has been shown to have potent antitumor effects in various clinical and pre-clinical studies, making it an important candidate for cancer immunotherapy. 6 These studies demonstrate that the therapeutic mechanism mediated by IL-12 is associated with the promotion of Th1 immunity and activation of the cytotoxic T lymphocytes (CTLs) or natural killer (NK) cells. In addition, IL-12 also inhibits tumor angiogenesis by inducing antiangiogenic factors, such as Mig and IP-10. 7 The cytokine granulocyte-monocyte colony-stimulating factor (GM-CSF) is a potent stimulator of hematopoiesis. This cytokine is also able to stimulate proliferation, maturation and function of antigen-presenting cells (APCs). Dranoff et al. 8 reported that the subcutaneous injection of GM-CSF-secreting whole tumor cells elicited potent antitumor immunity, indicating that GM-CSF is a potential immunotherapeutic agent for cancer therapy.
The immune responses induced by IL-12 and GM-CSF are mediated by entirely different mechanisms. The main targets of IL-12 are T, NK and NKT cells, which are the main killer cells for direct killing of the cancer cells. In contrast, the principle target cells of GM-CSF in the immune response are APCs. GM-CSF enhances the processing and presentation of antigen by APCs to maintain and augment the adaptive immune response. Because both IL-12 and GM-CSF are effective therapeutic candidates and have a potential advantage in cancer therapy when they are used in combination, we selected both of these cytokines for cancer immunogene therapy in an attempt to strengthen the antitumor immune response and augment the therapeutic effects of IL-12 and GM-CSF alone.
Therapeutic manipulation of immune responses via the employment of cytokines is effective strategy for immunotherapy against tumor. 4 However, the systemic treatment of cytokines at a therapeutic dose can lead to serious toxicity both in cancer-bearing patients and in animal cancer models. 9, 10 In an effort to circumvent the limitations of systemic cytokine administration, local injection of recombinant cytokine protein has been tried but it was still not easily amenable in the clinics, because it is the rapid decline in the cytokine expression within the tumors. 11 Oncolytic adenoviral (Ad) vectors are recently known as an intratumoral delivery system that has excellent therapeutic cytokine gene transduction efficiency. [12] [13] [14] [15] Oncolytic Ad can kill the tumor cells, as well as amplify expression of transgenes, by continuously replicating in the tumor cells until the tumor tissues were eradicated. 16 Hence, cytokine-encoding oncolytic Ad can drive sustained secretion of therapeutic level of cytokine long enough to generate antitumor immunity effectively in the local tumor tissue, resulting in prolongation of the antitumor effect and attenuated systemic toxicity compared with treatment of recombinant cytokine protein. In our previous studies, locally high expression of cytokines in the tumor tissues by oncolytic Ad elicited potent antitumor immune response with no serious toxicity. [12] [13] [14] Moreover, the therapeutic efficacy of intratumoral injection has not been significantly affected by circulating Ad-specific neutralizing antibodies, not like when Ad was delivered by intravenous injection. [17] [18] [19] These reports are further supported by some evidence that antibody penetration into the tumors may be minimal. 20, 21 In this present report, we generated an oncolytic Ad co-expressing IL-12 and GM-CSF (Ad-DB7/IL12/GMCSF) to evaluate the antitumor effects in a murine melanoma model. Data from this study demonstrate that mice treated with Ad-DB7/IL12/GMCSF have enhanced antitumor responses compared with mice treated with an oncolytic Ad expressing IL-12 or GM-CSF alone. In addition, we show that the enhanced antitumor effect was associated with augmentation of antitumor immune memory, increase of Th1 cytokines and prevention of tumor-induced thymic atrophy. Taken together, these results indicate that the utilization of IL-12 and GM-CSF for cancer gene therapy may induce synergistic therapeutic effects and suggest the potential application of Ad-DB7/IL12/GMCSF in the treatment of human cancers.
RESULTS

Construction of IL-12-and GM-CSF-expressing oncolytic Ad
To generate oncolytic Ad expressing both IL-12 and GM-CSF, the genes encoding murine IL-12 and GM-CSF were inserted into the E1 and E3 region of oncolytic Ad, Ad-DB7, respectively 16 (Figure 1a) . The expression level of IL-12 and GM-CSF produced from these newly generated Ads was then assessed. To accomplish this, B16-F10 cells were infected with different doses of Ad-DB7/IL12, Ad-DB7/GMCSF or Ad-DB7/IL12/GMCSF. After 2 days of infection, the level of IL-12 or GM-CSF secreted into the supernatant was measured by conventional enzyme-linked immunosorbent assay (ELISA). As shown in Figure 1b , the secreted levels of IL-12 and GM-CSF increased in a dose-dependent manner in the Ad-infected B16-F10 cells. Of interest, the level of GM-CSF expression induced by Ad-DB7/IL12/GMCSF infection was notably higher than the level induced by the Ad-DB7/ GMCSF infection. In contrast, the level of IL-12 expression induced by Ad-DB7/IL12/GMCSF was lower than the level induced by Ad-DB7/ IL12 infection. These data suggest that expression of an additional transgene in the E1 or E3 region of Ad genome may negatively or positively affect expression of the transgene in the other region. Similar phenomena was also observed in our previous studies, and the mechanism of this phenomenon remains unclear. 14 To evaluate whether the replication and oncolysis of Ad-DB7/IL12, Ad-DB7/GMCSF and Ad-DB7/IL12/GMCSF were different from the cognate control Ad, Ad-DB7, we performed a cytopathic effects assay. Three different types of human cancer cell lines (DU145, Hep1 and A549) were infected with Ad-DB7, Ad-DB7/IL12, Ad-DB7/GMCSF or Ad-DB7/IL12/GMCSF at multiplicity of infections (MOIs) of 0.1, 0.5, 1, 5, 10, 50 and 100. A replication-incompetent Ad, dE1/lacZ, was also used in this assay as a negative control. As shown in Figure 1c , the cytopathic effects forming ability of Ad-DB7/IL12, Ad-DB7/GMCSF or Ad-DB7/IL12/GMCSF was almost equivalent to Ad-DB7, indicating that high expression level of IL-12 and GM-CSF does not significantly affect the replication and oncolysis of the Ad.
Therapeutic efficacy of oncolytic Ad coexpressing IL-12 and GM-CSF in a murine melanoma model The antitumor effect of an oncolytic Ad coexpressing IL-12 and GM-CSF was compared with an oncolytic Ad expressing IL-12 or GM-CSF alone in the B16-F10 syngeneic model. Tumors were injected with phosphate-buffered saline (PBS), Ad-DB7, Ad-DB7/IL12, Ad-DB7/GMCSF or Ad-DB7/IL12/GMCSF every other day for three total injections, beginning when the average size of the tumor was 80-100 mm 3 . As shown in Figure 2a , we observed aggressive progression of the tumor in the mice treated with PBS alone and the average tumor volume in these mice exceeded 3000 mm 3 9 days after the final treatment. However, tumor growth was significantly inhibited in the cytokine-expressing oncolytic Ads-treated groups, with the tumor volumes of the tumors in Ad-DB7/IL12-, Ad-DB7/ GMCSF-or Ad-DB7/IL12/GMCSF-treated mice being 163.6 ± 72.7, 826.6±243.4 and 12.9±9.5 mm 3 , respectively, on the 15th day following the final Ad or PBS injection. In mice treated with Ad-DB7/IL12, Ad-DB7/GMCSF or Ad-DB7/IL12/GMCSF, the tumor growth inhibition rate was 93.4%, 65.1% and 99.5%, respectively, compared with the Ad-DB7-treated group (2470.2±802.2 mm 3 ). In addition, IL-12 was more effective in inhibiting tumor growth than GM-CSF, even though we injected half of the amount of Ad in the Ad-DB7/IL12-or Ad-DB7/IL12/GMCSF-treated group compared with the Ad-DB7-or Ad-DB7/GMCSF-treated group. Interestingly, although tumor growth was effectively suppressed in both Ad-DB7/ IL12-and Ad-DB7/IL12/GMCSF-treated groups at early time-points, tumors treated with Ad-DB7/IL12 grew rapidly at later time-points. In contrast, mice treated with an oncolytic Ad coexpressing IL-12 and GM-CSF continued to suppress tumor growth at later time-points (Po0.01). In particular, complete remission was observed in seven out of eight mice that received Ad-DB7/IL12/GMCSF, whereas complete regression of the tumor was observed in zero out of eight mice treated with Ad-DB7/IL12. Together, our results indicate that IL-12 has a weak long-term effect in suppressing tumor growth, although it is an effective anticancer agent early in the tumor growth. The antitumor effect of IL-12 was amplified and extended when combined with GM-CSF. The rate of survival was also significantly greater in the mice treated with Ad-DB7/IL12/GMCSF, compared with the mice treated with one of the other three oncolytic Ads (Figure 2b ).
Histological and immunohistochemial analysis of tumor tissues
To investigate the mechanism of the antitumor effect, histochemical analysis was performed on tumor tissue sections treated with PBS, Ad-DB7, Ad-DB7/IL12, Ad-DB7/GMCSF or Ad-DB7/IL12/GMCSF at 3 days after final Ad injection. As demonstrated by the images in Figure 3 , there were extensive areas of necrotic tissue and substantial lymphocytic infiltration in the tumors treated with Ad-DB7/IL12 or Ad-DB7/IL12/GMCSF, compared with the tumors injected with one of the other Ads. Immunohistochemical staining of tumor tissues with CD4-, CD8-or NK-1.1-specific antibodies revealed more massive infiltration of CD4 + T cells, CD8 + T cells and NK cells in tumors from the Ad-DB7/IL12-and Ad-DB7/IL12/GMCSF-treated groups than those from the Ad-DB7-and Ad-DB7/GMCSF-treated groups. These data indicate that therapeutic doses of IL-12 expressed in the tumor tissue can strongly induce activation and recruitment of T cells as well as NK cells. Similarly, we observed a greater number of CD86 + APCs in the tumor tissues of mice treated with Ad-DB7/GMCSF or Ad-DB7/ IL12/GMCSF compared with those in the tumor tissues from the Ad-DB7-and Ad-DB7/IL12-treated groups. These results show that GM-CSF expression in the tumor tissue, although inefficient in causing T cell activation, strongly recruits APCs in situ. However, GM-CSF expression alone inefficiently recruited T cells into the tumor tissue. These results indicate that a strong antitumor immune response can be induced in the tumor tissue by intratumoral injection of oncolytic Ad coexpressing IL-12 and GM-CSF. Additionally, the mechanism of this antitumor immune response in mice treated with Ad-DB7/IL12/GMCSF is associated with the recruitment of APCs by GM-CSF and the activation of T cells by IL-12.
Generation of a tumor-specific immune response by Ad-DB7/IL12/ GMCSF treatment To evaluate the tumor-specific immune response induced by cytokineexpressing oncolytic Ads, we collected splenocytes from PBS-, Ad-DB7-, Ad-DB7/IL12-, Ad-DB7/GMCSF-or Ad-DB7/IL12/ GMCSF-treated mice and co-incubated the cells with pre-irradiated B16-F10 cells for 3 days. The splenocytes were then assessed for interferon-g (IFN-g)-secreting lymphocytes and tumor cell-specific CTL activity via IFN-g enzyme-linked immune spot (ELISpot) assay and 51 Cr release assay, respectively. As shown in Figure 4a , we observed a slight increase in IFN-g-secreting immune cell number in mice treated with Ad-DB7/GMCSF compared with the PBS-or Ad-DB7-treated mice. In contrast, we observed a greater number of IFN-gsecreting immune cells in Ad-DB7/IL12-treated mice, and an even greater number in mice treated with Ad-DB7/IL12/GMCSF (Po0.01). These data suggest that IL-12 more effectively induced Th1 immune responses over GM-CSF alone, and this response was significantly enhanced when combined with GM-CSF. Furthermore, splenocytes from mice treated with Ad-DB7/IL12/GMCSF induced more effective CTL activity than those from mice treated with Ad-DB7/IL12 or Ad-DB7/GMCSF (Po0.01). The CTL activity of splenocytes from mice treated with Ad-DB7/IL12, Ad-DB7/GMCSF or Ad-DB7/IL12/ GMCSF was 14.56%, 9.19% and 18.54%, respectively ( Figure 4b ). Taken together, these results indicate that the induction of a tumorspecific immune response is synergistically enhanced when IL-12 and GM-CSF are expressed together in the tumor tissue.
T-cell-mediated antitumor immunity induced by Ad-DB7/IL12/ GMCSF in vivo
To verify the mechanism of Ad-DB7/IL12/GMCSF-mediated therapeutic benefit in vivo, T cell depletion experiments were carried out by treating B16-F10 melanoma-bearing mice with anti-CD4 or anti-CD8 antibodies. The loss of CD4 + or CD8 + T cells resulted in a significant increase in tumor volume compared with normal IgG-treated mice (Po0.01) ( Figure 5 ), suggesting that both CD4 + and CD8 + T cells are essential and are associated with the therapeutic efficacy of intratumoral injections with Ad-DB7/IL12/GMCSF.
Memory immune responses induced by treatment with Ad-DB7/ IL12/GMCSF
To evaluate whether antitumor immune memory is induced by the treatment with cytokine-expressing oncolytic Ads, we established a two-tumor model, which is described in the Materials and methods and Supplementary Figure 1 . After 8 days of Ads injection into the primary tumor, mice were rechallenged with a second dose of B16-F10 tumor cells in the other side of the abdomen. Tumor growth in the secondary site was significantly inhibited in the Ad-DB7/IL12/ GMCSF-treated group compared with the Ad-DB7-, Ad-DB7/IL12-or Ad-DB7/GMCSF-treated groups (Figure 6a , Po0.01). Specifically, the second tumor volume in the Ad-DB7-, Ad-DB7/IL12-, Ad-DB7/ GMCSF-or Ad-DB7/IL12/GMCSF-treated groups was 347.3 ± 47.9, 281.8 ± 2.7, 223.7 ± 12.3 and 40.1 ± 26.9 mm 3 , respectively, on day 28 after the rechallenge. Interestingly, the oncolytic Ad expressing GM-CSF alone was much more efficient at inducing a memory response versus the oncolytic Ad expressing IL-12. However, Ad-DB7/IL12 induced a better antitumor response at the primary tumor site compared with the Ad-DB7/GMCSF. These results suggest that GM-CSF has a more significant role in inducing the antitumor memory immune response, while IL-12 has a more significant role in the primary antitumor response.
We further evaluated the memory immune response by characterizing the phenotype of splenocytes from tumor-challenged, Ad-treated mice in terms of CD44, CD62L and CD127 expression (central memory T cell: CD44 high CD127 high CD62L high and effector memory T cell: CD44 high CD127 high CD62L low ). 22, 23 As shown in Figure 6b , both the populations of CD4 + -and CD8 + -effector memory T cells (CD44 high CD127 high CD62L low ) were significantly increased in the mice treated with Ad-DB7/IL12/GMCSF compared with the Ad-DB7/IL12-or Ad-DB7/GMCSF-treated groups (Po0.01), demonstrating that the strongest memory response was induced in mice treated with Ad-DB7/IL12/GMCSF. Moreover, the subsets of CD4 + -and CD8 + -effector memory T cells in the Ad-DB7/GMCSF-treated group were elevated over the Ad-DB7/IL12-treated groups (Po0.01), which is consistent with a better antitumor response at the secondary tumor site. Taken together, these results indicate that GM-CSF effectively promotes immune memory formation and that this memory is significantly augmented when GM-CSF is combined with IL-12.
Increased Th1 cytokines in the tumor tissues treated with Ad-DB7/ IL12/GMCSF The shift from Th1 to Th2 cytokine expression, which generates development and progression of malignant tumors, has been reported in a variety of mouse and human cancers, and an inverse association between upregulation of Th2-type cytokines and therapeutic benefit to cancer patients has also been reported. 24, 25 Therefore, we next evaluated whether cytokine expression from oncolytic Ads could polarize toward Th1 immune response from Th2 immune response in the tumor microenvironment. Tumor tissues from animal at 3 days after the last viral treatment were obtained and assessed with Th1/Th2/ Th17 cytometric bead assay kit (BD Biosciences PharMingen, Prevention of tumor-induced thymic atrophy by Ad-DB7/IL12/ GMCSF treatment Thymic atrophy has often been observed in tumor-bearing mice and contributes to the suppression of host immunity against the tumor. 26,27 Therefore, prevention of thymic atrophy is important in overcoming tumor-induced immunosuppression. In this study, we examined changes in the thymus volume and thymocyte number in tumor-bearing mice that received oncolytic Ads treatment. As demonstrated in Figure 8b , we observed no visible thymic atrophy in mice treated with Ad-DB7/IL12 or Ad-DB7/IL12/GMCSF. In contrast, we noted obvious thymic atrophy in tumor-bearing mice treated with PBS, Ad-DB7 or Ad-DB7/GMCSF. Moreover, the number of thymocytes in tumor-bearing mice was substantially decreased 13 days after the final treatment with PBS, Ad-DB7 or Ad-DB7/GMCSF. Although treatment with Ad-DB7 or Ad-DB7/GMCSF slightly recovered thymic atrophy, the effect was very limited. In marked contrast, the number of thymocytes was significantly elevated in the mice treated with either Ad-DB7/IL12 or Ad-DB7/IL12/GMCSF, and thymocyte number was inversely correlated with the tumor volume (Figure 8c ). These results imply that thymic atrophy is induced by tumor growth and can be prevented by intratumoral expression of IL-12, with or without GM-CSF.
To further explore the thymic changes in mice treated with PBS, Ad-DB7, Ad-DB7/GMCSF, Ad-DB7/IL12 or Ad-DB7/IL12/GMCSF, we performed histological and immunohistochemical staining on the thymic tissue. We observed normal morphology in the thymus tissue, which was segregated into the obvious cortex and medulla zones in all groups of mice at both 1 and 4 days after Ad treatment (Figure 9a) . However, the thymic structure was abnormally disrupted in the mice treated with PBS, Ad-DB7 or Ad-DB7/GMCSF on day 13 after treatment. In marked contrast, normal thymic structure was maintained in mice treated with Ad-DB7/IL12 or Ad-DB7/IL12/GMCSF. Data from a TUNEL assay demonstrated that more extensive apoptosis was induced in the thymic tissues from mice treated with PBS, Ad-DB7 or Ad-DB7/GMCSF, compared with thymi from those treated with Ad-DB7/IL12 or Ad-DB7/IL12/GMCSF (Figure 9b ). Furthermore, active proliferation of thymocytes in the thymus was evident by positive proliferating cell nuclear antigen staining in mice treated with Ad-DB7/IL12 or Ad-DB7/IL12/GMCSF versus other Ads (Figure 9c ). These results suggest that Ad-DB7/IL12 and Ad-DB7/ IL12/GMCSF are able to prevent thymic atrophy in tumor-bearing mice via inhibition of apoptosis and induction of proliferation in the thymus.
Inhibition of vascular endothelial growth factor (VEGF) expression in tumor-bearing mice by Ad-DB7/IL12/GMCSF treatment A previous study reported that thymic atrophy in tumor-bearing mice was induced by tumor-derived factors such as VEGF. 28 To determine whether VEGF expression is affected by intratumoral expression of GM-CSF and/or IL-12, the level of VEGF protein in the tumor tissue and serum was measured after intratumoral injection of PBS, Ad-DB7, Ad-DB7/GMCSF, Ad-DB7/IL12 or Ad-DB7/IL12/GMCSF. As shown in Figure 10a , VEGF expression was decreased in the tumor tissue from all virus-treated groups compared with the PBS-treated group. In particular, VEGF was more significantly decreased in the tumors from mice treated with Ad-DB7/IL12 or Ad-DB7/IL12/GMCSF, compared with those from mice treated with Ad-DB7 or Ad-DB7/GMCSF (Po0.05), indicating that IL-12 is a strong inhibitor of VEGF protein levels in tumor tissue. We speculate that decreased VEGF expression in tumors leads to the reduced serum levels of VEGF. However, the level of VEGF in the serum was undetectable, except in the serum from the PBS-treated group (Figure 10b) . Thus, we were not able to compare serum VEGF levels between the Ads-treated groups.
DISCUSSION
There are many advantages to using cytokine gene therapy as a type of cancer immunotherapy. The restricted expression of cytokines only in the tumor tissues can induce a strong antitumor immune response without causing significant systemic toxicity or other side effects. 3 Moreover, the expression level of the transgene can be amplified Gene therapy using oncolytic adenovirus-expressing IL-12 and GM-CSF K-J Choi et al according to the replication of the vector. 29 In addition, oncolytic Ad can be easily genetically engineered to deliver more than two therapeutic genes into one vector. 13 These advantages indicate a strong therapeutic potential for combined immunotherapy using oncolytic Ads in the treatment of cancer. 30 The synergistic therapeutic effects of combination therapy are due to the different biological actions of each expressed gene, promoting a multifocal antitumor immune response. In our previous studies, we have demonstrated that the therapeutic potential of IL-12 is enhanced by combining this cytokine with other immune stimulatory factors such as B7.1 or 4-1BBL. 12, 14 In addition, other groups have also reported that synergistic antitumor effects are elicited when more than two cytokines are used together for cancer therapy. 31 IL-12 induces potent antitumor immunity by promoting Th1 differentiation of CD4 + T cells and stimulating CTLs and NK cell cytotoxicity. However, IL-12 mainly targets immune effector cells such as T and NK cells, rather than APCs. 32 In contrast, GM-CSF has little direct effect on T or NK cells, but it is a potent stimulator for APCs. In combination gene therapy, local expression of IL-12 and GM-CSF may function to induce a potent T or NK cell-mediated antitumor immune response and amplify the effector phase of the immune response by enhancing the processing and presentation of tumor antigens to effector/memory T cells, respectively.
In this study, we have demonstrated that Ad-DB7/IL12/GMCSF enhanced the antitumor effects over either Ad-DB7/IL12 or Ad-DB7/ GMCSF, suggesting that the synergistic antitumor effect is elicited when IL-12 and GM-CSF is administered in combination, compared with the treatment with either cytokine alone (Figure 2) . Moreover, subsequent experiments demonstrated that the therapeutic effect was caused by a CD4 + and CD8 + T cell-mediated Th1 antitumor immune response (Figures 3 and 5) . Notably, treatment with Ad-DB7/IL12/ GMCSF significantly increased the number of CD86 + APCs that infiltrated into the tumor tissue, compared with treatment with either Ad-DB7/IL12 or Ad-DB7/GMCSF, suggesting that coexpression of both IL-12 and GM-CSF creates a tumor microenvironment favorable to the recruitment of APCs. Furthermore, ELISpot and 51 Cr release assay also confirmed that a stronger Th1 antitumor immune response was induced by treating mice with Ad-DB7/IL12/GMCSF (Figure 4) . Importantly, the IFN-g-secreting cell population was significantly greater in mice treated with Ad-DB7/IL12/GMCSF versus Ad-DB7/ IL12, indicating that GM-CSF acts as a potent adjuvant for amplifying IL-12-induced Th1 immunity.
Interestingly, there was remarkable suppression of tumor growth in mice treated with Ad-DB7/IL12 or Ad-DB7/IL12/GMCSF up to 13 days after the final Ad treatment (Figure 2 ). However, we observed that the tumor rapidly grew in the mice treated with Ad-DB7/IL12 after 13 days post-treatment, indicating that there is no long-term effect of suppressing tumor growth, despite the fact that Ad-DB7/IL12 had potent antitumor effect in the early stages of treatment. In contrast, seven out of eight mice in the Ad-DB7/IL12/GMCSF-treated group achieved complete tumor regression and survived over 90 days, suggesting that more potent and prolonged antitumor immunity can be induced by treatment with Ad-DB7/IL12/GMCSF versus Ad-DB7/ IL12. It should be noted that cures or long-term survival has been rarely reported in experiments using this aggressive B16-F10 tumor model. Helguera et al. 33 reported that long-term immunity induced by an antibody-IL-12 fusion protein combined with an antibody-GM-CSF fusion protein is due to the formation of systemic long-term immune memory. Immune memory is mediated by the adaptive immune system, with memory cells forming a more efficient and prolonged immune response versus the response produced by naïve lymphocytes. 34 In this present study (Figure 6) , tumor growth at a secondary site was significantly suppressed by the treatment with Ad-DB7/IL12/ GMCSF compared with treatment with either Ad-DB7/IL12 or Ad-DB7/GMCSF. Moreover, the splenocytes from mice treated with Ad-DB7/IL12/GMCSF had a greater population of cells that expressed molecules indicative of a memory phenotype. This formation of strong immune memory was induced by treatment with Ad-DB7/ IL12/GMCSF, which led to suppression of tumor growth at a distant site. In addition, Ad-DB7/GMCSF more effectively induced immune memory versus Ad-DB7/IL12, even though Ad-DB7/GMCSF was insufficient in reducing the primary tumor burden in situ, indicating that GM-CSF promotes immune memory more effectively than IL-12. The greater effectiveness of GM-CSF in immune memory formation may be due to enhanced antigen processing and presentation to activate and expand effector/memory T cells. Moreover, the formation of immune memory induced by GM-CSF was synergistically enhanced when combined with IL-12. Taken together, these data indicate that injecting Ad-DB7/IL12/GMCSF into a primary tumor effectively reduces the tumor burden by inducing a strong antitumor Th1 immune response through the action of IL-12 early in the antitumor response. Furthermore, long-term suppression of tumor growth is maintained by promotion of an antitumor immune memory response that is mediated by GM-CSF at a later stage in the antitumor response. These results further suggest that treatment with Ad-DB7/IL12/ GMCSF not only suppresses local solid tumor growth and prevents recurrence, but may also treat tumors present at distant sites due to metastasis.
The thymus is a primary lymphoid organ and is the major site of T cell maturation. Therefore, function of the thymus is closely associated with T cell development. Previous studies have reported that thymic atrophy occurs in the tumor-bearing mice. 26, 27 More importantly, Zhang 35 has shown that young patients with malignant tumors exhibited severe involution of the thymus. Thymic atrophy suppresses T cell development and T cell-mediated immunity, resulting in impaired immune responses in the tumor-bearing host. 36 Therefore, prevention of thymic atrophy in tumor-bearing mice is critical for maintaining a targeted immune response against the malignancy. In our study, thymic atrophy was tightly associated with the tumor size, suggesting that tumor growth is an immediate cause of thymic atrophy in tumor-bearing mice. Furthermore, thymic atrophy was effectively prevented by treating mice with Ad-DB7/IL12/ GMCSF or Ad-DB7/IL12, which was associated with reduced apoptosis and the induction of proliferation in the thymus (Figures 8  and 9 ). These data suggest that IL-12 may have a critical role in the prevention of thymic atrophy in tumor-bearing mice. Currently, there are no studies showing that IL-12 can prevent thymic atrophy induced by a tumor. Although a previous study has reported that IL-12 augments IL-7-or IL-2-induced thymocyte proliferation, resulting in the prevention of age-related thymus involution, 37 the mechanism of thymic atrophy induced by tumor growth, as is the case in our study, is a pathological process that differs entirely from the agerelated physiological involution of the thymus. Therefore, these reported data are insufficient to explain why the tumor-induced thymic atrophy was prevented by intratumoral injection of the oncolytic Ad expressing IL-12. Furthermore, although it has been previously reported that GM-CSF is able to augment thymocyte proliferation, 38 our data showed that GM-CSF is less effective than IL-12 in preventing tumor-induced thymic atrophy.
VEGF is a protein produced by most tumors that stimulates neoangiogenesis and promotes tumor development. Additionally, VEGF directly inhibits dendritic cell differentiation and maturation to suppress the immune response. 39 Previous studies have reported that VEGF induces thymic atrophy in tumor-bearing mice and contributes to tumor-induced immunosuppression. 28 These data suggest that inhibition of VEGF expression is important to overcome the immunosuppressive effects of the tumor, as well as to prevent thymic atrophy in tumor-bearing mice. Our results show that VEGF expression is significantly reduced in the tumor tissue from mice treated with oncolytic Ad coexpressing IL-12 and GM-CSF or IL-12 alone (Figure 10 ). IL-12 has been reported to be a strong inhibitor of VEGF expression within the tumor, 40 which may be a possible mechanism to explain how tumor-induced thymic atrophy was prevented by treatment with IL-12-expressing oncolytic Ads. We hypothesize that tumor-induced thymic atrophy was elicited by VEGF secretion in the tumor tissue, which circulated through the blood stream. Therefore, we speculate that the reduction of VEGF expression mediated by IL-12 was the main factor in preventing thymic atrophy. In addition, a reduction in VEGF expression was of great significance to the maintenance of the antitumor immune response in tumor-bearing mice, and the creation of a suitable microenvironment for potent cancer immunotherapy.
In summary, the data from this study demonstrate for the first time the potent antitumor effects of an oncolytic Ad co-expressing IL-12 and GM-CSF in a murine melanoma model. In addition, the synergistic antitumor effect was based on the induction of a tumorspecific Th1 immune response, elevation of Th1 cytokines in the tumor tissues and reversal of thymic atrophy in tumor-bearing mice. Furthermore, we showed that long-term antitumor effects were driven by a GM-CSF-induced systemic immune memory response, indicating a potential for IL-12/GM-CSF combination therapy for the clinical treatment of cancer in humans.
MATERIALS AND METHODS
Cell culture
The B16-F10 (murine melanoma cells; Seoul National University Cell Bank, Seoul, Korea), 293 cell (adenoviral E1-transformed human embryonic kidney cells; ATCC, Manassas, VA, USA) and NIH 3T3 (murine fibroblast; ATCC) were maintained in Dulbecco's Modified Eagle's Medium (Gibco BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco BRL), 2 mM L-glutamine, 100 IU ml À1 penicillin and 100 mg ml À1 streptomycin.
Generation of Ads expressing IL-12 and GM-CSF
To generate an Ad expressing IL-12 and GM-CSF at the E1 and E3 region, respectively, we first constructed an E3 shuttle vector expressing GM-CSF. The murine GM-CSF gene was excised from pCDNA3.1-GMCSF (ATCC) with NheI and XhoI and subcloned into the Ad E3 shuttle vector, pSP72-E3, 41 generating pSP72-GMCSF. The newly constructed pSP72-GMCSF shuttle vector was linearized by digestion with ScaI, and then co-transformed with a replication-incompetent Ad total vector, dl324/Bst 16 into Escherichia coli BJ5183, Figure 10 Reduced VEGF expression in tumor tissue from mice treated with Ad-DB7/IL12/GMCSF. B16-F10 murine melanoma cells (5Â10 5 ) were injected into the abdomen of C57BL/6 mice. When tumors had grown to 80-100 mm 3 in volume (8-10 days after tumor implantation), tumors were treated with PBS, Ad-DB7, Ad-DB7/IL12, Ad-DB7/GMCSF or Ad-DB7/IL12/GMCSF every other day for three total administrations, and collected on day 3 post-treatment. Level of VEGF protein in the tumor tissue (a) and serum (b) was measured by conventional VEGF ELISA kit. Each data point indicates mean ± s.e. of triplicates of representative of three independent experiments. *Po0.05 versus Ad-DB7/GMCSF-treated group.
which was digested with SpeI to allow for homologous recombination, yielding the Ad plasmid pdl/GMCSF. The structure of the resulting recombinant vector was confirmed by restriction enzyme digestion and PCR analysis.
To construct an Ad E1 shuttle vector expressing IL-12, a murine IL-12 gene (p35/IRES/p40) was excised from pCA14-IL12 12 using SnaBI and SalI, and subcloned into the replication-competent E1 shuttle vector, pAd-DB7, 16 producing the pDB7/IL12 Ad E1 shuttle vector. The Ad E1 shuttle vector was then linearized by digestion with NdeI, and co-transformed into E. coli BJ5183 with BstBI-digested pdl/GMCSF to allow for homologous recombination and the generation of Ad-DB7/IL12/GMCSF. The proper recombinant Ad plasmid was digested with PacI and transfected into 293 cells to generate the oncolytic Ad, Ad-DB7/IL12/GMCSF (Figure 1a) . All viruses were propagated in 293 cells, purified by CsCl density purification, dissolved in storage buffer (10 mM Tris, 4% sucrose and 2 mM MgCl 2 ) and stored at À80 1C. Viral particle numbers were calculated from measurements of the optical density at 260 nm (OD 260 ), where one absorbency unit is equivalent to 10 12 viral particles per milliliter, and infectious titers (plaque-forming unit (PFU) per milliliter) were determined by limiting dilution assay on 293 cells. The ratio of PFU to viral particle for Ad-DB7, Ad-DB7/GMCSF, Ad-DB7/IL12 and Ad-DB7/IL12/GMCSF used in this study is 1:61, 1:70, 1:23 and 1:20, respectively. The MOI was calculated from infectious titers (PFU).
GM-CSF and IL-12 ELISA
B16-F10 melanoma cells were plated onto six-well plates at 3Â10 4 cells per well, and then infected with Ad-DB7/GMCSF, Ad-DB7/IL12 or Ad-DB7/IL12/ GMCSF at different MOIs. At 48 h post-infection, the supernatant was harvested and the levels of IL-12p70 and GM-CSF were determined by conventional ELISA kit (R&D Systems, Minneapolis, MN, USA).
Cytopathic effect assay
To assess whether virally expressed IL-12 and GM-CSF altered the ability of the Ad to replicate, cytopathic effects values, which directly correlate with the degree of viral replication, were compared. Cells were plated onto 24-well plates at approximately 30-80% confluence, and then infected with dE1/lacZ, Ad-DB7, Ad-DB7/IL12, Ad-DB7/GMCSF or Ad-DB7/IL12/GMCSF at MOIs of 0.1-100. The killing effect of the virus was visually monitored daily by microscopy. When cells infected with virus exhibited complete cell lysis at low MOI, the dead cells were washed out, and cells on the plate were stained with 0.5% crystal violet in 50% methanol.
Fluorescence-activated cell sorting (FACS) analysis of the splenocytes
For the assessment of T cell population phenotype, the spleens were harvested 3 days after the last Ad treatment of mice bearing a B16-F10 tumor. The spleens were minced into single-cell suspensions in PBS plus 2% fetal bovine serum, and treated with EDTA-ammonium chloride solution (0.15 M NH 4 Cl, 1 mM KHCO 3 and 0.1 mM EDTA) to remove red blood cells. For assessment of the memory T-cell population, splenocytes were stained with PerCP-CY5.5-conjugated anti-CD4 or anti-CD8 (BD Biosciences), phycoerythrin-conjugated anti-CD44 (eBioscience, San Diego, CA, USA), fluorescein isothiocyanateconjugated anti-CD62L (eBioscience) or APC-conjugated anti-CD127 (eBioscience) monoclonal antibodies for four-color FACS analysis. Cells were then fixed with 1% paraformaldehyde in PBS. Samples were analyzed using a BD Biosciences BD-LSR II Analytic Flow Cytometer and FACSDiva software (BD Biosciences).
IFN-c ELISpot assay
The splenocytes were harvested by mincing the spleen and red blood cells were lysed as described above in 'FACS analysis of the splenocytes' . The splenocytes were then co-cultured with irradiated B16-F10 cells (5000 rad) for 3 days in the presence of recombinant human IL-2 (100 U ml À1 ). ELISpot plates (Millipore, Bedford, MA, USA) were coated with murine IFN-g monoclonal antibody at 4 1C overnight. Splenocytes were then serially diluted from 1Â10 5 to 1Â10 6 cells per well and added into the ELISpot plates. The splenocytes were then treated with phorbol 12-myristate 13-acetate (Sigma, Steinheim, Germany) at 50 ng ml À1 as a positive control, and the culture media was added into plate well without splenocytes as a negative control. After 24 h of incubation, plates were incubated with biotinylated anti-IFN-g antibody for 2 h and then with streptavidin horseradish peroxidase (Pharmingen) for 1 h. Spots were developed by a 3-amino-9-ethyl-carbazole conjugate substrate (Pharmingen). The number of spots, corresponding to IFN-g-secreting cells, was determined with a KS-ELISpot (Zeiss-Kontron, Oberkochen, FRG).
Cr release assay
The cytolytic activity of CTLs was determined by standard 51 Cr release assay. The splenocytes were collected from mice at 3 days after the final treatment with Ad and co-cultured with pre-irradiated B16-F10 or NIH3T3 cells for 5 days in culture medium supplemented with human IL-2 (100 U ml À1 ). After 5 days of culture, splenocytes were harvested from culture dishes to serve as effector cells along with the 51 Cr-labeled B16-F10 or NIH3T3 cells as target cells. Both the effector cells and target cells were transferred into 96-well plates at two different target-to-effector cell ratios (1:10, 1:100) and incubated at 37 1C. After 4 h of incubation, the supernatant was harvested and 51 Cr release was measured. The percentage of cytotoxicity was determined from the following formula: % specific cytotoxicity¼((experimental release-spontaneous release)/(maximum release-spontaneous release))Â100.
Histology and immunohistochemistry
For histological examination, the tumor tissues or thymi were fixed in 10% neutral buffered formalin, embedded in paraffin and cut into 4-mm sections. Representative sections were stained with hematoxylin and eosin and examined by light microscopy. For the detection of lymphocytes and DCs, tumor tissues were frozen in O.C.T compound (Sakura Finetec, Torrance, CA, USA) and cut into 10-mm sections. The cryosections were incubated with rat antimouse CD4 monoclonal antibody (Pharmingen), rat antimouse CD8 monoclonal antibody (Pharmingen), mouse antimouse NK-1.1 monoclonal antibody (Biolegend, San Diego, CA, USA) or rat antimouse CD86 monoclonal antibody (Pharmingen) as a primary antibody, and then with horseradish peroxidase-conjugated goat antirat IgG (Pharmingen) or horseradish peroxidase-conjugated goat antimouse IgG (Southern Biotech, Birmingham, AL, USA) as a secondary antibody. Diaminobenzidine/hydrogen peroxidase (DAKO, Copenhagen, Denmark) was used as the chromogen substrate. All slides were counterstained with Meyer's hematoxylin. For the detection of proliferating cells, slides were deparaffinized in xylene and then hydrated by incubation in a graded series of alcohols. Endogenous peroxidase activity in the sections was blocked with 3% hydrogen peroxide. The antiproliferating cell nuclear antigen monoclonal antibody, PC10 (DAKO), was first allowed to bind with Real/Envision secondary antibody (DAKO). Mouse serum was added to the complexed primary and secondary antibodies to minimize potential interaction between free secondary antibody and mouse immunoglobulin in the tissue section. The sections were then incubated with the primary/secondary antibody complex, and the sections were subsequently incubated with streptavidin-peroxidase. Diaminobenzidine/ hydrogen peroxidase (DAKO) was used as the chromogen substrate.
TUNEL assay
The apoptotic thymocyte population was assessed by TUNEL assay as described previously. 42 The apoptotic cells were visually identified in five randomly selected fields and photographed at a magnification of Â400.
Tumor model and animal study B16-F10 murine melanoma cells (5Â10 5 ) were resuspended in 100 ml Hank's balanced salt solution and injected into the abdomen of 6-8-week-old male C57BL/6 mice (Japan SLC, Tokyo, Japan). When tumors had grown to 80-100 mm 3 in volume (8-10 days after tumor cell implantation), PBS or Ads (Ad-DB7, Ad-DB7/GMCSF, Ad-DB7/IL12 and Ad-DB7/IL12/GMCSF) were injected intratumorally (Ad-DB7, Ad-DB7/GMCSF: 1Â10 8 PFU per tumor in 30 ml of PBS, Ad-DB7/IL12 and Ad-DB7/IL12/GMCSF: 5Â10 7 PFU per tumor in 30 ml of PBS) every other day for a total of three injections. Tumor growth was monitored every other day by measuring the length and width of the tumor with a caliper and calculating the tumor volume on the basis of the following formula: volume¼0.523LW 2 .
For the evaluation of the memory immune response elicited by cytokineexpressing oncolytic Ads, 5Â10 5 cells of B16-F10 were first injected subcutaneously into the right abdomen of mice to generate the primary tumor. When the tumors grew to a volume of 60-70 mm 3 (6-7 days after tumor cell implantation), the mice received 1Â10 8 PFU in 30 ml PBS of each oncolytic Ad into the primary tumor every other day for a total of four injections. After 8 days of the final viral injection, mice were rechallenged with 5Â10 5 B16F10 cells injected into the left abdominal region of the mice. Growth of the second tumor was monitored every day as described above.
To deplete CD4 + or CD8 + T cells in vivo, mice were administrated intravenously with 200 mg anti-CD4 (clone GK1.5; DiNonA, Seoul, Korea) or anti-CD8 (clone 53-6.7; DiNonA) neutralizing antibodies 2 days before virus injection and once every 5 days thereafter for an additional 15 days. The control group received isotype-matched antibody (BioXCell, West Lebanon, NH, USA). Depletion of the corresponding CD4 + or CD8 + cells was 495%, as confirmed by FACS analysis of the spleen cells from treated mice (data not shown).
The thymus harvest and thymocyte count B16-F10 murine melanoma cells suspended in 100 ml Hank's balanced salt solution were injected into the abdominal area of 6-8-week-old male C57BL/6 mice. When tumors reached to 80-100 mm 3 in volume (8-10 days after tumor implantation), mice were treated with Ads (1Â10 8 PFU per tumor in 30 ml of PBS) injected into the tumor every other day for a total of three injections. On days 1, 4 and 13 after injection of the virus, thymi were removed and immediately placed in RPMI 1640 medium. After a single-cell suspension was prepared, the number of thymocytes was determined using a hemocytometer.
Quantification of VEGF and Th1/Th2/Th17 profile
The tumor tissues were homogenized (ART-MICCRA D-8; ART moderne Labortechnik, Munchen, Germany) in ice-cold RIPA buffer (ELPIS-Biotech, Taejean, Korea) with a proteinase inhibitor cocktail (Sigma). Homogenates were then centrifuged in a high-speed microcentrifuge for 10 min and determined for total protein content using a bicinchoninic acid protein assay reagent kit (Pierce, Rockford, IL, USA). Levels of VEGF in the tumor tissue extract and serum were determined by ELISA according to instructions from the manufacturer (R&D). Th1/Th2/Th17-type cytokine expression profiles in the tumor tissue extract were assessed using Th1/Th2/Th17 cytometric bead assay kit (BD Biosciences Pharmingen). ELISA and cytometric bead assay data were normalized relative to the total protein concentration in each tumor and were calculated as nanograms or picograms per milligram of total protein.
Statistical evaluation
All data are expressed as mean±s.e. Statistical analyses of the data were performed using the two-tailed Student t-test (SPSS 13.0 software; SPSS, Chicago, IL, USA). P-values less than 0.05 were considered statistically significant (*, Po0.05; **, Po0.01). Analysis of variance was used for multiple group comparisons to determine the potential antitumor effects between the groups.
